Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alere Inc Receives FDA Approval For Alere Determine HIV-1/2 Ag/Ab Combo


Friday, 9 Aug 2013 09:57am EDT 

Alere Inc announced that it has received U.S. Food and Drug Administration (FDA) approval of its pre-market application (PMA) to market Alere Determine HIV 1/2 Ag/Ab Combo in the United States for the detection of HIV-1 p24 antigen and antibodies to HIV-1/HIV-2. The FDA approval allows Alere to market Alere Determine HIV 1/2 Ag/Ab Combo as a CLIA (Clinical Laboratory Improvement Amendments) moderately complex medical device. 

Company Quote

38.59
0.06 +0.16%
22 Jul 2014